Assay News and Research

RSS

PPD and VirtualScopics partner to provide medical imaging services

PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

26 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies "Biosimilars" for the Treatment of Cancer.

26 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Vitro signs contract with HemoGenix to manufacture, distribute stem cell analysis tools

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.

20 Oct 2010

Spectral commences pivotal Toraymyxin trial for severe sepsis

Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.

20 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

biOasis receives final report on Collaborative Research project from UBC

biOasis Technologies Inc. has received a final report detailing results achieved within the Collaborative Research project with The University of British Columbia (UBC) that was announced by the Company on June 2, 2009.

19 Oct 2010

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

PTC announces ataluren Phase 2b efficacy data at International Congress

PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.

18 Oct 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

Researchers develop new lab test for diagnosing preeclampsia

In as many as 8 percent of pregnancies worldwide, women who seem fine for months develop preeclampsia, a serious complication causing symptoms including high blood pressure, severe swelling, and problems with placental development. The untreatable and unpredictable condition, with no known cause, often requires premature delivery, and can sometimes kill the mother and the fetus.

15 Oct 2010

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.

14 Oct 2010

Detect-Ready MRSA assay receives first independent validation

Molecular Detection Inc. a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Assay News and Research

PPD and VirtualScopics partner to provide medical imaging services

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Researchers create new high-content assay to increase human embryonic stem cell survival

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Vitro signs contract with HemoGenix to manufacture, distribute stem cell analysis tools

Spectral commences pivotal Toraymyxin trial for severe sepsis

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

biOasis receives final report on Collaborative Research project from UBC

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

PTC announces ataluren Phase 2b efficacy data at International Congress

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Researchers develop new lab test for diagnosing preeclampsia

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Detect-Ready MRSA assay receives first independent validation

New evidence supports possible link between XMRV and prostate cancer

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News